Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal

This article was originally published in PharmAsia News

Executive Summary

Takeda is the latest big pharma paying its way into Alnylam's not-so-exclusive club, with the firm having agreed to pay Alnylam $150 million upfront in exchange for worldwide, non-exclusive access to its RNA interference therapeutics platform technology in two therapeutic areas: oncology and metabolic disease
Advertisement

Related Content

"A Quantum Leap In Resources": Millennium CEO Dunsire In A Conversation On The Firm's First Year As Part Of Takeda (Part 1 Of 2)
RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway
RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway
Takeda Weaves Worldwide Web Of Partnerships In Quest For Innovative Drugs, CEO Says
Kyowa Hakko Enters Antibody Space With Alnylam RNAi RSV Therapy
Pharma Business Structure, M&As Evolving To Create Smaller Cross-Functional Units
Takeda And Cell Genesys Ink $270 Million Development Deal for GVAX Immunotherapy
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
Takeda Makes $1 Billion Move For Amgen Development Rights
Advertisement
UsernamePublicRestriction

Register

SC068578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel